APO-DECIDE

Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

 Coordinatore ROYAL COLLEGE OF SURGEONS IN IRELAND 

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Prof.
Nome: Jochen
Cognome: Prehn
Email: send email
Telefono: 35314022261
Fax: 35314022447

 Nazionalità Coordinatore Ireland [IE]
 Sito del progetto http://www.apodecide.eu/
 Totale costo 3˙896˙336 €
 EC contributo 2˙999˙482 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-11-01   -   2014-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Prof.
Nome: Jochen
Cognome: Prehn
Email: send email
Telefono: 35314022261
Fax: 35314022447

IE (DUBLIN) coordinator 932˙803.80
2    OncoMark Limited

 Organization address address: Weston Park 76
city: DUBLIN 14
postcode: -

contact info
Titolo: Ms.
Nome: Mairin
Cognome: Rafferty
Email: send email
Telefono: +353 1 7163666
Fax: +353 1 716 3709

IE (DUBLIN 14) participant 508˙000.00
3    OPTIMATA LTD

 Organization address address: ABBA HILLEL STREET 7
city: RAMAT GAN
postcode: 52522

contact info
Titolo: Dr.
Nome: Marina
Cognome: Kleiman
Email: send email
Telefono: 97237519226

IL (RAMAT GAN) participant 461˙160.00
4    UNIVERSITE PARIS DESCARTES

 Organization address address: Rue de l'Ecole de Medecine 12
city: PARIS
postcode: 75270

contact info
Titolo: Dr.
Nome: Adeline
Cognome: Lassaux
Email: send email
Telefono: 33176531748

FR (PARIS) participant 362˙400.00
5    QUEEN'S UNIVERSITY BELFAST

 Organization address address: University Road
city: BELFAST
postcode: BT7 1NN

contact info
Titolo: Mrs.
Nome: Colleen
Cognome: Spence
Email: send email
Telefono: +4428 9097 5183
Fax: +4428 9097 5182

UK (BELFAST) participant 353˙442.00
6    KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET

 Organization address address: Theodor Stern Kai 7
city: FRANKFURT AM MAIN
postcode: 60590

contact info
Titolo: Prof.
Nome: Simone
Cognome: Fulda
Email: send email
Telefono: +49 69 6786 6557
Fax: +49 69 6786 65 9157

DE (FRANKFURT AM MAIN) participant 316˙876.20
7    PINTAIL LTD

 Organization address address: SPRINGHILL AVENUE 77
city: BLACKROCK

contact info
Titolo: Mr.
Nome: Ciaran
Cognome: Clissmann
Email: send email
Telefono: +353 1 2899529

IE (BLACKROCK) participant 64˙800.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

material    chemotherapy    drug    tumour    therapy    resistance    cancer    apoptosis    pathways    fu    treatment    tools    clinical    decision    crc    medicine    egfr    patient    personalised    anti    smes    signalling    largely   

 Obiettivo del progetto (Objective)

'With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with the success of such treatments being largely unpredictable. 5-FU-based chemotherapy represents the main stay of CRC therapy. DNA damaging agents such as 5-FU and anti-EGFR therapy seek to induce tumour regression through induction of apoptosis or sensitization to apoptosis. Dysfunctional apoptosis is well recognized as a key contributing factor in chemotherapy resistance. The aim of the APODECIDE consortium is to develop systems medicine tools that predict treatment responses in CRC patients to 5-FU-based chemotherapy and anti-EGFR therapy, based on a systems analysis of apoptosis and EGFR signalling pathways. Based on previous clinical proof-of-concept studies that demonstrated the unique potential of such approaches in predicting tumour resistance, the APO-DECIDE consortium aims to deliver new clinical decision making tools that enable personalised medicine approaches and ‘smart’ clinical trials design in the future. The SMEs will benefit from the project through the development of systems-based combinatorial biomarkers adapted to formalin fixed paraffin-embedded material, the routine material used in clinical histopathology, hence providing a unique opportunity for marketing and exploitation. SMEs and their academic partners will also develop computational whole body models reflecting drug pharmacodynamics and pharmacokinetics in patient cohorts, providing a unique market niche in the field clinical oncology.'

Altri progetti dello stesso programma (FP7-HEALTH)

FUTURAGE (2009)

FUTURAGE: A Roadmap for Ageing Research

Read More  

ATP (2009)

Access to Pharmaceuticals

Read More  

SAGHE (2009)

Safety and Appropriateness of Growth hormone treatments in Europe

Read More